Abstract
Background Obesity is associated with obstructive sleep apnea (OSA) and cardiovascular risk. Positive airway pressure (PAP) is the first line treatment for OSA, but evidence on its beneficial effect on major adverse cardiovascular events (MACE) prevention is limited. Using claims data, the effects of PAP on mortality and incidence of MACE among Medicare beneficiaries with OSA were examined.
Methods A cohort of Medicare beneficiaries with ≥2 distinct OSA claims was defined from multi-state, state-wide, multi-year (2011-2020) Medicare fee-for-service claims data. Evidence of PAP initiation and utilization was based on PAP claims after OSA diagnosis. MACE was defined as a composite of myocardial infarction, heart failure, stroke, or coronary revascularization. Doubly robust Cox proportional hazards models with inverse probability of treatment weights estimated treatment effects controlling for sociodemographic and clinical factors.
Results Among 888,835 beneficiaries with OSA (median age 73 years; 43.9% women; median follow-up 1,141 days), those with evidence of PAP initiation (32.6%) had significantly lower all-cause mortality (HR [95%CI]: 0.53 [0.52-0.54]) and MACE incidence risk (0.90 [0.89-0.91]). Higher quartiles of annual PAP claims were progressively associated with lower mortality (Q2: 0.84 [0.81-0.87], Q3: 0.76 [0.74-0.79], Q4: 0.74 [0.72-0.77]) and MACE incidence risk (Q2: 0.92 [0.89-0.95], Q3: 0.89 [0.86-0.91], Q4: 0.87 [0.85-0.90]).
Conclusion PAP utilization was associated with lower all-cause mortality and MACE incidence among Medicare beneficiaries with OSA. Results might inform trials assessing the importance of OSA therapy towards minimizing cardiovascular risk and mortality in older adults.
Competing Interest Statement
Dr. Krishna Sundar was a past advisory board member for Resmed Inc. and is the co-founder of Hypnoscure LLC through the University of Utah Technology Commercialization Office All other authors declared no conflicts of interest.
Funding Statement
The study was funded by the American Heart Association (20CDA35310360), Patient-Centered Outcomes Research Institute (RI-CRN-2020-003-IC); NIH CTSA NCATS Frontiers: University of Kansas Clinical and Translational Science Institute (UL1TR002366); Tier 2 grant, University of Missouri.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed by the Institutional Review Board of the University of Missouri-Columbia on behalf of each participating institution of the Greater Plains Collaborative (Allina Health, Indiana University, Intermountain Healthcare, Marshfield Clinic, Medical College of Wisconsin, University of Iowa, University of Kansas Medical Center, University of Nebraska Medical Center, University of Texas Health Sciences Center at San Antonio, University of Texas Southwestern, University of Utah, Washington University in St. Louis) and determined to be minimal risk and therefore approved the waiver of authorization under the Privacy Rule. 45 CFR 164.512 (i)(1)(i)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The study incorporated additional Medicare claims data from 2018-2020, substantially increasing the sample size. As a consequence, all reported estimates have been updated, including figures and supplemental materials. The conclusions were very similar with some additional results that are discussed in greater detailed in this version.
Abbreviations list
- ATE
- average treatment effect
- CCI
- Charlson comorbidity index
- CI
- confidence interval
- CMS
- Centers for Medicare & Medicaid Services
- COPD
- chronic obstructive pulmonary disease
- CPAP
- continuous positive airway pressure
- CV
- cardiovascular
- DME
- durable medical equipment
- HF
- heart failure
- HR
- hazards ratio
- MACE
- major adverse cardiovascular events
- MI
- myocardial infarction
- OSA
- obstructive sleep apnea
- PAP
- positive airway pressure
- PS
- propensity scores
- RCT
- randomized controlled trials.
